Delcath Systems (NASDAQ:DCTH) Stock Jumps 7.2% on Strong Earnings

Key Points

• Delcath shares rose 7.2% after quarterly results beat expectations: EPS was $0.17 versus consensus for a $0.09 loss, and revenue reached $35.1 million versus an estimate of $26.0 million.
• Management forecast 2026 revenue of $115 million–$117 million, above analyst consensus of about $106.2 million, and aims to have at least 36 active treatment centers by year-end.
• HC Wainwright and BTIG raised their price targets to $36 and $25, respectively, while maintaining Buy ratings; analysts’ average rating is Moderate Buy, with a $29.33 consensus target.

Shares of Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) traded up 7.2% on Tuesday following a better than expected earnings announcement. The stock traded as high as $21.84 and last traded at $21.7290. 533,561 shares were traded during trading, an increase of 14% from the average session volume of 468,296 shares. The stock had previously closed at $20.27.

The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.26. The company had revenue of $35.10 million during the quarter, compared to the consensus estimate of $25.99 million. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Q3 results topped estimates: Delcath reported earnings of $0.17 per share versus analysts’ expected loss of about $0.09, while revenue of $35.1 million exceeded the $26.0 million consensus. Earnings also improved from $0.02 per share a year earlier. Zacks Q3 earnings report
• Positive Sentiment: Management guided to FY 2026 revenue of $115 million–$117 million, above the approximately $106.2 million analyst consensus. It also set a goal of having at least 36 active centers by year-end, supporting expectations for continued commercial expansion. Delcath revenue guidance and active-center target
• Positive Sentiment: HC Wainwright raised its price target to $36 from $32 and maintained a Buy rating. BTIG Research also raised its target, to $25 from $21, and kept its Buy rating—both moves signal stronger analyst confidence. HC Wainwright recommendations BTIG Research recommendations

Wall Street Analyst Weigh In

DCTH has been the topic of a number of recent research reports. HC Wainwright lifted their target price on Delcath Systems from $32.00 to $36.00 and gave the company a "buy" rating in a research report on Tuesday. BTIG Research upped their price objective on Delcath Systems from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Monday. Zacks Research lowered shares of Delcath Systems from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, October 6th. Wall Street Zen upgraded shares of Delcath Systems from a "hold" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Weiss Ratings lowered shares of Delcath Systems from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Two analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Delcath Systems currently has an average rating of "Moderate Buy" and a consensus target price of $29.33.

Hedge Funds Weigh In On Delcath Systems

Several institutional investors and hedge funds have recently added to or reduced their stakes in DCTH. Russell Investments Group Ltd. boosted its holdings in Delcath Systems by 31.1% in the third quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company's stock worth $1,417,000 after purchasing an additional 21,069 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Delcath Systems in the second quarter worth about $1,362,000. Alps Advisors Inc. grew its holdings in shares of Delcath Systems by 30.3% in the third quarter. Alps Advisors Inc. now owns 45,640 shares of the company's stock valued at $729,000 after purchasing an additional 10,600 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Delcath Systems by 54.0% in the 1st quarter. Bank of America Corp DE now owns 57,729 shares of the company's stock worth $536,000 after purchasing an additional 20,249 shares during the period. Finally, Kopp Family Office LLC bought a new position in Delcath Systems during the third quarter valued at $450,000. Hedge funds and other institutional investors own 61.12% of the company's stock.

Delcath Systems Price Performance

The company has a 50-day simple moving average of $15.53 and a 200-day simple moving average of $12.49. The firm has a market cap of $754.00 million, a PE ratio of 2,170.67 and a beta of 0.62.

About Delcath Systems

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company's proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.